A revolution in collaboration models is fundamentally changing the business of healthcare. In an effort to lower costs and expand access—and maybe to avoid antitrust laws—partnerships between seemingly unlikely and even unrelated organizations are becoming the norm. Is it also true in the public health world, where issues with costs and access can prevent care delivery to those who may need it most?
As baby boomers are reaching retirement, and the general population is living longer with more active lifestyles, the projected number of total knee arthroplasty (TKA) and total hip arthroplasty (THA) procedures for the Medicare and commercial patient population is expected to increase. Removing total joint procedures from the inpatient-only list enables cost reduction that results from performing these cases in the outpatient setting.
Join ECG Principal's Naya Kehayes and Sean Hartzell for an insightful session.
ECG Principal and ASC Practice Leader, Naya Kehayes will sharing her perspective on the future of managed care contracting for spine, orthopedics, and pain management in ASCs.
In this Q&A, meet Hector Torres: a former investment banker, an M&A lawyer, and a healthcare consultant. Learn how Hector’s robust background helps him provide multifaceted solutions for clients.
This article discusses best practices for building and maintaining affiliation agreements between health systems and universities as the healthcare market continues to evolve and both parties seek to maximize the strategic advantages of their partnership.
In the following infographic, we outline “what to expect when you’re expecting” a transformation at your organization, our own play on the best-selling book about planning for a big change.
Organizations that applied for the CMS Bundled Payments for Care Improvement (BPCI) Advanced model are eagerly awaiting data from CMS. What will they do with it once it arrives?
Last Friday, President Trump, with the help of Health and Human Services Secretary Alex Azar, unveiled the administration’s “Blueprint to Lower Drug Prices.” As this issue was a central tenet of President Trump’s 2016 campaign platform, guidance on the administration’s approach to tackling drug prices has long been anticipated.
Page 26 of 291